Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety
and tolerability of magrolimab in combination with other anticancer therapies and to
determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with
relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab +
daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib +
dexamethasone.
The primary objective of this study for the Dose Expansion Cohorts is to evaluate the
efficacy of magrolimab in combination with other anticancer therapies in participants with
relapsed/refractory multiple myeloma as determined by objective response rate (ORR).